Dr. Natasha Leighl and her team at University Health Network published their pilot data on using liquid biopsy testing earlier in a lung cancer patient's journey. Usually, 1) patients with severe enough symptoms of respiratory issues will be imaged. 2) Images and clinical presentation of potential lung cancer will be referred for biopsy. 3) Tissue biopsy will be used to diagnose lung cancer (i.e. pathological diagnosis). 4) Biomarker testing is done on tissue. 5) Patients receive targeted therapy if druggable mutation is found. In Dr. Leighl's study, her team used Follow It through our testing program after step 2. This shortened time from referral to treatment by half (60 days to 30 days). Congratulations to everyone, especially to the clinical team for continuing to process samples day-in and day-out. This study is an example of ICH having an immediate impact on patients and having long-term effects on cancer care.
December 7, 2022
Read about the history of the Human Genome Project.
December 1, 2022
The holiday season is around the corner and we would like to inform everyone of our operation schedule over Christmas and New Year.
November 15, 2022
The entire month of November is Lung Cancer Awareness Month. ICH is opening up the conversation to showcase how our distributed data-driven approach is improving health equity in lung cancer cures.
October 24, 2022
We’re thrilled to announce that Imagia Canexia Health is a finalist for the Reuters Events Pharma Awards, in the Driving Health Equity category.
September 22, 2022
Appointment fortifies Imagia Canexia Health’s board with leading expertise in successfully scaling biopharma and diagnostics enterprises
August 30, 2022
NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting